Browse Category

NASDAQ:RVMD News 7 January 2026 - 8 January 2026

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

New York, January 8, 2026, 05:14 (EST) — Premarket AbbVie Inc (ABBV) shares slipped 1.6% to about $229.64 in premarket trading on Thursday after the drugmaker denied it was in talks to buy cancer biotech Revolution Medicines and cut its 2025 profit view. Revolution’s stock fell 11.5% in extended trading after AbbVie’s statement, Reuters reported. Investing.com+1 The whiplash matters because AbbVie has become a deal story again, and the market is quick to mark it up or down on anything that hints at the next growth lever. The company is due to report full-year and fourth-quarter 2025 results on Feb.
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

New York, Jan 7, 2026, 18:35 EST — After-hours AbbVie (ABBV.N) shares were down about 1% at $231.11 in after-hours trading on Wednesday after the drugmaker denied a Wall Street Journal report that it was in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), saying it “is not in discussions with Revolution Medicines.” The stock had closed up 4.2% at $233.42, while Revolution shares slid 11.5% late after jumping nearly 30% earlier, with the report pointing to a valuation around $20 billion. AbbVie has spent more than $20 billion on acquisitions since 2023 as its former blockbuster Humira lost
AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

AbbVie circles Revolution Medicines in possible $20 billion-plus deal: WSJ, Bloomberg

New York, Jan 7, 2026, 16:14 (EST) AbbVie (ABBV.N) is in advanced talks to buy cancer-drug developer Revolution Medicines (RVMD.O), the Wall Street Journal reported on Wednesday, citing people familiar with the matter. Revolution shares jumped nearly 30% after the report, while AbbVie rose more than 5%. https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-talks-buy-biotech-revolution-medicines-wsj-reports-2026-01-07/ For AbbVie, a takeover would also sharpen its push to add new growth drivers as its former blockbuster Humira faces steeper competition after patent protection ended. It would put AbbVie deeper into oncology at a time when big drugmakers are still paying up for late-stage cancer assets. https://www.wsj.com/business/deals/abbvie-near-deal-for-revolution-medicines-eca830a1 The Journal did not

Stock Market Today

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

Walmart stock jumps to $131 as traders brace for CPI and Feb. 19 earnings

7 February 2026
Walmart shares rose 3.3% Friday to $131.18, up 10% since Jan. 30, as the Dow closed above 50,000 for the first time. The retailer’s market value crossed $1 trillion this week. Investors await January inflation data on Feb. 13 and Walmart’s quarterly results on Feb. 19 for signs of continued momentum.
Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

Caterpillar stock price jumps 7% to $726 as Dow cracks 50,000 — what matters next week

7 February 2026
Caterpillar shares surged 7.1% to $726.20 Friday, driving the Dow above 50,000 for the first time. The move erased recent losses and followed insider selling by Group President Bob De Lange earlier in the week. Deere and CNH Industrial also gained as investors rotated into industrial stocks. Markets await next week’s U.S. jobs and inflation data.
Amazon stock slides as $200B AI spending plan meets cautious profit outlook

Amazon stock slides as $200B AI spending plan meets cautious profit outlook

7 February 2026
Amazon shares fell 9% Friday after the company announced plans for $200 billion in 2026 capital spending, mainly for AWS and AI, and issued a first-quarter profit outlook below estimates. The stock drop could erase $200 billion in market value. Fourth-quarter net sales rose 14% to $213.4 billion, while free cash flow declined due to higher spending on AI infrastructure.
Go toTop